<div id="readability-page-1"><p>Avaii Wealth Management LLC decreased its holdings in  Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 81.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,992 shares of the biopharmaceutical company's stock after selling 66,729 shares during the period. Avaii Wealth Management LLC's holdings in Bristol Myers Squibb were worth $676,000 as of its most recent SEC filing.</p><div><p><span></span><span>Get <strong>Bristol Myers Squibb</strong> alerts:</span></p></div><ul><li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li></ul><p>Several other institutional investors have also made changes to their positions in the stock. Advocate Group LLC lifted its position in  Bristol Myers Squibb by 1.5% during the 3rd quarter. Advocate Group LLC now owns 156,594 shares of the biopharmaceutical company's stock worth $7,062,000 after acquiring an additional 2,355 shares during the last quarter.  Nicholas Wealth LLC. increased its stake in shares of  Bristol Myers Squibb by 31.0% in the third quarter. Nicholas Wealth LLC. now owns 31,247 shares of the biopharmaceutical company's stock worth $1,409,000 after purchasing an additional 7,394 shares during the period.  Allspring Global Investments Holdings LLC lifted its position in shares of  Bristol Myers Squibb by 81.1% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 970,647 shares of the biopharmaceutical company's stock worth $46,038,000 after purchasing an additional 434,745 shares during the last quarter.  Merit Financial Group LLC boosted its stake in  Bristol Myers Squibb by 27.1% during the 3rd quarter. Merit Financial Group LLC now owns 52,673 shares of the biopharmaceutical company's stock valued at $2,376,000 after purchasing an additional 11,238 shares during the period.  Finally, Consilium Wealth Advisory LLC acquired a new stake in  Bristol Myers Squibb in the 3rd quarter valued at approximately $927,000. 76.41% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of analysts have weighed in on the stock. BMO Capital Markets  reissued a &#34;market perform&#34; rating on shares of Bristol Myers Squibb in a report on Monday, November 17th. HSBC  reaffirmed a &#34;hold&#34; rating and set a $53.00 price objective on shares of Bristol Myers Squibb in a research report on Wednesday, December 10th. Citigroup decreased their target price on Bristol Myers Squibb from $48.00 to $45.00 and set a &#34;neutral&#34; rating on the stock in a research report on Monday, November 17th. Wells Fargo &amp; Company upped their price target on Bristol Myers Squibb from $53.00 to $55.00 and gave the company an &#34;equal weight&#34; rating in a report on Wednesday, December 10th. Finally, Morgan Stanley  reiterated an &#34;underweight&#34; rating and issued a $37.00 price objective (up previously from $36.00) on shares of Bristol Myers Squibb in a research report on Friday, December 12th. Six research analysts have rated the stock with a Buy rating, fourteen have issued  a Hold rating and one  has issued  a Sell rating to the stock. According to data from MarketBeat, the company  has a consensus rating of &#34;Hold&#34; and a consensus price target of $54.62.</p><ul><li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li></ul><p><b>Read Our Latest Report on Bristol Myers Squibb</b></p><h2>Bristol Myers Squibb Stock Performance</h2><p>Shares of NYSE:BMY opened at $53.93 on Thursday. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $63.33. The business has a 50-day moving average price of $49.42 and a two-hundred day moving average price of $47.43. The company has a current ratio of 1.27, a quick ratio of 1.17 and a debt-to-equity ratio of 2.39. The stock has a market capitalization of $109.79 billion, a P/E ratio of 18.22, a P/E/G ratio of 8.30 and a beta of 0.29. </p><ul><li>MarketBeat Week in Review – 02/03 - 02/07</li></ul><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating analysts' consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The company had revenue of $12.22 billion during the quarter, compared to analysts' expectations of $11.75 billion. During the same period in the prior year, the business posted $1.80 EPS. Bristol Myers Squibb's revenue was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS.  Equities analysts predict that  Bristol Myers Squibb Company will post 6.74 earnings per share for the current year. </p><h2>Bristol Myers Squibb Increases Dividend</h2><p>The company also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Investors of record on Friday, January 2nd will be issued a dividend of $0.63 per share. The ex-dividend date is Friday, January 2nd. This is a boost from Bristol Myers Squibb's previous quarterly dividend of $0.62. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.7%. Bristol Myers Squibb's dividend payout ratio  is 83.78%. </p><h2>Bristol Myers Squibb Profile</h2> (Free Report)<p>Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.  </p><p>BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.</p><h2>See Also</h2><ul><li>Five stocks we like better than Bristol Myers Squibb</li><li>The Best $1 You'll Spend This Holiday Season</li><li>Holiday surprise: $1 gets you everything</li><li>America’s “most deplorable” Christmas sale</li><li>Market Panic: Trump Just Dropped a Bomb on Your Stocks</li><li>Your family's wealth expires in 2026?</li></ul><p><strong>Want to see what other hedge funds are holding BMY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Avaii Wealth Management LLC has reduced its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 81.7% in Q3, now owning 14,992 shares valued at $676,000. Other institutional investors have also adjusted their positions, with Advocate Group LLC increasing its stake by 1.5% and Allspring Global Investments Holdings LLC boosting its holdings by 81.1%. Analysts have mixed ratings on the stock, with a consensus rating of "Hold" and a price target of $54.62. Bristol Myers Squibb reported a Q3 EPS of $1.63, exceeding estimates, and revenue of $12.22 billion, up 2.8% year-over-year.</p>

Avaii Wealth Management LLC Has $676,000 Stock Holdings in Bristol Myers Squibb Company $BMY